共 50 条
MiR-142-3p enhances chemosensitivity of breast cancer cells and inhibits autophagy by targeting HMGB1
被引:60
|作者:
Liang, Lu
[1
,2
,3
]
Fu, Jijun
[1
,2
,3
]
Wang, Siran
[4
]
Cen, Huiyu
[1
,2
,3
]
Zhang, Lingmin
[1
,2
,3
]
Mandukhail, Safur Rehman
[1
,2
,3
]
Du, Lingran
[1
,2
,3
]
Wu, Qianni
[1
,2
,3
]
Zhang, Peiquan
[1
,2
,3
]
Yu, Xiyong
[1
,2
,3
]
机构:
[1] Guangzhou Med Univ, Key Lab Mol Target & Clin Pharmacol, Sch Pharmaceut Sci, Guangzhou 511436, Peoples R China
[2] Guangzhou Med Univ, Sch Pharmaceut Sci, State Key Lab Resp Dis, Guangzhou 511436, Peoples R China
[3] Guangzhou Med Univ, Affiliated Hosp 5, Guangzhou 511436, Peoples R China
[4] Harbin Med Univ, Dept Prosthodont, Affiliated Hosp 2, Harbin 150001, Peoples R China
基金:
中国国家自然科学基金;
关键词:
Breast cancer;
MCF-7 cell line;
HMGB1;
MiR-142-3p;
Drug resistance;
Chemosensitivity;
DOWN-REGULATION;
TUMOR-CELLS;
MICRORNA-142-3P;
EXPRESSION;
RADIOSENSITIVITY;
CHEMOTHERAPY;
INFLAMMATION;
CONTRIBUTES;
PROGRESSION;
SENSITIZES;
D O I:
10.1016/j.apsb.2019.11.009
中图分类号:
R9 [药学];
学科分类号:
1007 ;
摘要:
MiR-142-3p has been reported to act as a tumor suppressor in breast cancer. However, the regulatory effect of miR-142-3p on drug resistance of breast cancer cells and its underlying mechanism remain unknown. Here, we found that miR-142-3p was significantly downregulated in the doxorubicin (DOX)-resistant MCF-7 cell line (MCF-7/DOX). MiR-142-3p overexpression increased DOX sensitivity and enhanced DOX-induced apoptosis in breast cancer cells. High-mobility group box 1 (HNIGB1) is a direct functional target of miR-142-3p in breast cancer cells and miR-142-3p negatively regulated HNIGB1 expression. Moreover, overexpression of HMGB1 dramatically reversed the promotion of apoptosis and inhibition of autophagy mediated by miR-142-3p up-regulation. In conclusion, miR-142-3p overexpression may inhibit autophagy and promote the drug sensitivity of breast cancer cells to DOX by targeting HNIGB1. The miR-142-3p/HNIGB1 axis might be a novel target to regulate the drug resistance of breast cancer patients. (C) 2020 Chinese Pharmaceutical Association and Institute of Materia Medica, Chinese Academy of Medical Sciences. Production and hosting by Elsevier B.V.
引用
收藏
页码:1036 / 1046
页数:11
相关论文